An interventional study of Infliximab and Rituximab in Wegener's Granulomatosis, Churg-Strauss Syndrome and Microscopic Polyangiitis, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-11-19.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment
The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.
The aim of this study is to compare the efficacy of rituximab versus infliximab in relapsing or refractory forms of ANCA+ vasculitides (Microscopic Polyangiitis, Wegener's granulomatosis and Churg-Strauss syndrome).
107 studies on the registry are indexed under Granulomatosis with Polyangiitis; 19 are open to participants now.
This study's enrollment of 20 is below the median of 68 across 68 interventional studies indexed under Granulomatosis with Polyangiitis.
Browse Granulomatosis with Polyangiitis studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,576 studies on the registry; 1,028 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rituximab
Drug: Rituximab
Infliximab
Drug: Infliximab
Infliximab
Rituximab
Partial or complete remission of the vasculitides
Time frame: one year
To study the safety and adverse effects of both regimens
Time frame: one year
Microscopic polyangiitis
Time frame: one year
Wegener's granulomatosis
Time frame: one year
Churg-Strauss syndrome
Time frame: one year
This study is completed, as verified in Mar 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Infliximab · Rituximab
Granulomatosis with Polyangiitis →
Assistance Publique - Hôpitaux de Paris →